Publications by the researcher in collaboration with Inmaculada Pérez Camacho (9)

2024

  1. A comprehensive, predictive mortality score for patients with bloodstream infections (PROBAC): a prospective, multicentre cohort study

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 8, pp. 1794-1800

  2. Association of microbiological factors with mortality in Escherichia coli bacteraemia presenting with sepsis/septic shock: a prospective cohort study

    Clinical Microbiology and Infection, Vol. 30, Núm. 8, pp. 1035-1041

  3. Clinical characteristics, predisposing factors and outcomes for Enterococcus faecalis versus Enterococcus faecium bloodstream infections: a prospective multicentre cohort study

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 43, Núm. 10, pp. 2011-2022

  4. Early Antibiotic De-escalation in Patients With Severe Infections Due to Bloodstream Infection by Enterobacterales: A Post Hoc Analysis of a Prospective Multicentre Cohort

    International Journal of Antimicrobial Agents, Vol. 64, Núm. 5

  5. Whole-genome characterisation of Escherichia coli isolates from patients with bacteraemia presenting with sepsis or septic shock in Spain: a multicentre cross-sectional study

    The Lancet Microbe, Vol. 5, Núm. 4, pp. e390-e399

2023

  1. Conventional Hospitalization versus Sequential Outpatient Parenteral Antibiotic Therapy for Staphylococcus aureus Bacteremia: Post-Hoc Analysis of a Multicenter Observational Cohort

    Antibiotics, Vol. 12, Núm. 1

2022

  1. Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 5, pp. 1452-1460

2021

  1. Revisiting the epidemiology of bloodstream infections and healthcare-associated episodes: results from a multicentre prospective cohort in Spain (PRO-BAC Study)

    International Journal of Antimicrobial Agents, Vol. 58, Núm. 1

2017

  1. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection

    Clinical Microbiology and Infection, Vol. 23, Núm. 6, pp. 409.e5-409.e8